These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15373800)

  • 21. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
    Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
    J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
    [No Abstract]   [Full Text] [Related]  

  • 23. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B-RAF and melanocytic neoplasia.
    Gill M; Celebi JT
    J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF mutations in conjunctival melanoma.
    Gear H; Williams H; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of BRAF mutations in Spitz nevi.
    Gill M; Renwick N; Silvers DN; Celebi JT
    J Invest Dermatol; 2004 May; 122(5):1325-6. PubMed ID: 15140238
    [No Abstract]   [Full Text] [Related]  

  • 27. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lucky draw in the gene raffle.
    Pollock PM; Meltzer PS
    Nature; 2002 Jun; 417(6892):906-7. PubMed ID: 12087387
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunogenicity of constitutively active V599EBRaf.
    Andersen MH; Fensterle J; Ugurel S; Reker S; Houben R; Guldberg P; Berger TG; Schadendorf D; Trefzer U; Bröcker EB; Straten Pt; Rapp UR; Becker JC
    Cancer Res; 2004 Aug; 64(15):5456-60. PubMed ID: 15289355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF as a potential therapeutic target in melanoma and other malignancies.
    Tuveson DA; Weber BL; Herlyn M
    Cancer Cell; 2003 Aug; 4(2):95-8. PubMed ID: 12957284
    [No Abstract]   [Full Text] [Related]  

  • 31. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relief of inhibitory autophosphorylation activates RAF.
    Cancer Discov; 2013 Jul; 3(7):OF31. PubMed ID: 23847376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanocytic lesions, Spitz tumors, and Don Ferrante's logic.
    Urso C
    Am J Dermatopathol; 2007 Oct; 29(5):491-4. PubMed ID: 17890925
    [No Abstract]   [Full Text] [Related]  

  • 34. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
    Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating BRAF mutations in eruptive melanocytic naevi.
    Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
    Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
    Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
    J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Br J Dermatol; 2015; 172(5):1438-40. PubMed ID: 25323827
    [No Abstract]   [Full Text] [Related]  

  • 38. A genome-based strategy uncovers frequent BRAF mutations in melanoma.
    Pollock PM; Meltzer PS
    Cancer Cell; 2002 Jul; 2(1):5-7. PubMed ID: 12150818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of BRAF mutations in localized cutaneous melanoma.
    Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
    J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Models and mechanisms in malignant melanoma.
    Benjamin CL; Melnikova VO; Ananthaswamy HN
    Mol Carcinog; 2007 Aug; 46(8):671-8. PubMed ID: 17570501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.